[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617202":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":31,"locations":31,"responsibleParty":41,"collaborators":31,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":31,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":68,"whyStopped":31,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":31},{"fullName":5,"class":6},"Tanta University","OTHER",[8,15,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard asthma Controller Therapy Only","ACTIVE_COMPARATOR","30 children with moderate persistent asthma receiving standard controller therapy consisting of a combined low-dose inhaled corticosteroid (ICS) and long-acting β2-agonist (LABA), administered by metered-dose inhaler with spacer.",[13,14],"Dietary Supplement: Nigella sativa Oil Capsules (100 mg\u002Fkg\u002Fday)","Dietary Supplement: Nigella sativa Oil Capsules (50 mg\u002Fkg\u002Fday)",{"label":16,"type":17,"description":18,"interventionNames":19},"Standard Therapy + Nigella sativa (50 mg\u002Fkg\u002Fday)","EXPERIMENTAL","30 children with moderate persistent asthma receiving standard controller therapy plus Nigella sativa oil capsules at a dose of 50 mg\u002Fkg\u002Fday as adjunct therapy.",[13,20],"Drug: Fluticasone \u002F Long-Acting Beta-2 Agonist Combination",{"label":22,"type":17,"description":23,"interventionNames":24},"Standard Therapy + Nigella sativa (100 mg\u002Fkg\u002Fday)","30 children with moderate persistent asthma receiving standard controller therapy plus Nigella sativa oil capsules at a dose of 100 mg\u002Fkg\u002Fday as adjunct therapy.",[14,20],[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DIETARY_SUPPLEMENT","Nigella sativa Oil Capsules (100 mg\u002Fkg\u002Fday)","Nigella sativa oil administered orally in capsule form at a dose of 100 mg\u002Fkg\u002Fday as adjunct therapy.",[16,9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Nigella sativa Oil Capsules (50 mg\u002Fkg\u002Fday)","Nigella sativa oil administered orally in capsule form at a dose of 50 mg\u002Fkg\u002Fday as adjunct therapy.",[22,9],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":31},"DRUG","Fluticasone \u002F Long-Acting Beta-2 Agonist Combination","Low-dose inhaled corticosteroid (fluticasone propionate 200 µg\u002Fday) combined with a long-acting beta-2 agonist (two puffs every 12 hours), administered via metered-dose inhaler with spacer.",[22,16],{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"PRINCIPAL_INVESTIGATOR","Rehab Zaki Elmeazawy","Associate professor of pediatrics","100617202","efficacy-of-oral-nigella-sativa-as-adjuvant-therapy-in-children-with-moderate-persistent-asthma-100617202",false,"NCT07315555","Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma","Asthma","Inclusion Criteria:\n\n1. Children aged 6-18 years\n2. Diagnosed with moderate persistent asthma according to the Global Initiative for Asthma (GINA) 2022 guidelines\n3. Receiving stable standard controller therapy (inhaled corticosteroids ± long-acting β2-agonists) for at least 4 weeks prior to enrollment\n4. Able to perform reproducible spirometry\n\nExclusion Criteria:\n\n1. History of severe asthma exacerbation requiring ICU admission in the past 3 months\n2. Use of systemic corticosteroids within 4 weeks prior to enrollment\n3. Known hypersensitivity to Nigella sativa or its components\n4. Other chronic respiratory diseases (e.g., cystic fibrosis, bronchiectasis)\n5. Significant comorbidities (e.g., cardiac, renal, or hepatic disorders)\n6. Inability to comply with study procedures","ALL","6 Years","18 Years",{"count":56,"type":57},90,"ESTIMATED","INTERVENTIONAL",[60],"NA","Complementary and adjunctive therapies are increasingly being explored to enhance asthma control and reduce airway inflammation. Nigella sativa (black seed) is a medicinal plant used traditionally in multiple regions and has demonstrated anti-inflammatory, immunomodulatory, and bronchodilator effects. Its potential as an adjuvant therapy in asthma has attracted attention in both preclinical and clinical research",[63],"Community Acquired Pneumonia",[65,66,67],"Nigella sativa","Pneumonia","Pediatric","NOT_YET_RECRUITING","2025-12-18",{"date":71,"type":72},"2026-01-02","ACTUAL",{"date":74,"type":57},"2026-01-01",{"date":76,"type":57},"2026-10-31",{"name":5,"class":6}]